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Many  studies  on  prophylactic  immunization  against  pneumococcal pneu- 
monia have  been made,  using  a  number  of different  antigenic  preparations. 
Almost all investigators have concluded that immunization exerts a  beneficial 
effect.  In most of the studies, however, certain variables have clouded inter- 
pretation of the results.  Among the variables,  the following appear  to be of 
greatest moment: differences in the composition of the immunized and control 
groups;  uncertainty  as  to  whether  the  specific pneumococcal  types included 
in  the  immunizing  preparation  were  the  same  as  those  currently  causing 
pneumonia; failure  to  determine  whether  the  observed  decline  in  cases  in 
the immunized group was due to a decrease in cases caused by the pneumococcal 
types included  in  the  vaccine;  inadequate  control  of  the  antigenicity  of  the 
preparations used. 
The subject of antipneumococcal immunization has been reviewed  recently 
by Heffron  (1)  and  references will be made in  the  present paper  to  certain 
aspects only. 
The studies of Lister and Ordman (2) among native laborers in South Mrican mines 
between 1930 and 1934 suggest that immunization with a polyvalent pneumococcal 
vaccine reduces the incidence  of pneumonia caused by the same pneumococcal types. 
Pneumococci of types I, II, III~ V, VII, XII, and XIV were represented in the vaccine, 
* This investigation was a joint project of the Commission on Pneumonia, Board for the 
Investigation and Control of Influenza and other Epidemic Diseases in the Army, Office of 
The Surgeon General, U. S. Army, and the Army  Air Force Rheumatic Fever Control Program, 
Office  of The Air Surgeon. 
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1 cc. containing 1000 million organisms of each type, except for type II, of which 2000 
million per  cc.  were  included.  In  addition,  the  vaccine  contained  pneumococcus 
"type T" as well as varying numbers of Streptococcus pyogenes, Streptococcus salivarius, 
H. influenzae,  N. catarrhalis, Staphylococcus aureus hemolyticus,  and K. friedl~nderi. 
The total bacterial count of the vaccine was 11,000  million per cc.  The organisms 
were suspended in saline, killed by heating to 60°C. for 1 hour, and preserved with 
0.5 per cent phenol.  Admnistration was in three doses of 1 cc. subcutaneously  at 
intervals of 1 week.  The best results were obtained in the prevention of pneumonia 
caused by pneumococcus type II.  In the control group 27.9 per cent of the eases 
were caused by type II whereas in the vaccinated group this was reduced to 4.0 per 
cent.  With the other types represented in the vaccine a  beneficial effect was  also 
observed, but in no instance was as good as with type II.  In prior studies of Lister 
and Ordman, the prophylactic value of antipneumococcal immunization appeared to 
be less definite.  The studies of immunization in South Mriea carried out prior to 
1931 have been reviewed critically by Orenstein (3), who concluded that in only one 
instance the results "appeared to justify the adoption of prophylactic vaccination." 
Cecil and Austin (4) tested the effect of prophylactic vaccination against pneumo- 
coccal pneumonia at Camp Upton, New York, in 1918.  Three or four subcutaneous 
injections of vaccine were given at weekly intervals to  12,519  men.  The  vaccine 
consisted of a  saline suspension of heat-killed pneumococci types I, II, and III pre- 
served with 0.3 tricresol.  Each dose of 0.5 cc. contained 6000 to 9000 million organ- 
isms of each of types I  and II and 4500 to 6000  million of type III pneumococcus. 
During a  10 week period following vaccination, no  eases of pneumonia caused by 
types I, II, or III occurred among the immunized men, whereas in the control group 
of 19,400 men there were 26 cases of pneumonia caused by these types.  The validity 
of the data is lessened by differences in the composition of the vaccinated and control 
groups, since the vaccinated group was made up entirely of seasoned troops, whereas 
in the control group approximately 25 per cent were new recruits. 
Subsequent  studies by Cecil and  Vaughan  (5)  at Camp Wheeler, Georgia, were 
directed toward assessing the prophylactic effect of a  lipovaccine of pneumococci 
given in a single subcutaneous dose of 1 cc.  Each cubic centimeter contained 10,000 
million pneumococci of each of types I, II, and III.  Following vaccination, pneu- 
monia rates were lower in the inoculated than in the control group, although the 
differences were not as great as in the experience of Cecil and Austin (4) at Camp 
Upton, New York.  Rapid population changes and an epidemic of influenza at Camp 
Wheeler were felt to have influenced the results. 
Following the injection of saline suspensions of pneumococci, Cecil and Austin (4) 
observed the  development of  small sterile abscesses in  1.2  per cent of  inoculated 
subjects.  With the lipovaccine the incidence of local reactions at the site of inocula- 
tion was only 0.04 per cent.  General reactions severe enough to require hospitaliza- 
tion occurred in 0.2 per cent of subjects inoculated with saline suspensions of pneumo- 
cocci in the study of Cecil and Austin (4) and in 0.7 per cent of the subjects inoculated 
with lipovaccine (5). 
It has been demonstrated repeatedly that animals cart be protected against 
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specific capsular  polysaccharides.  Antibodies  to  the  somatic portion of the 
cell are of considerably less  importance in this respect.  Francis and Tillett 
(6) showed originally that the purified capsular polysaccharides of pneumococci 
are antigenic for man when injected intracutaneously in a single dose as small 
as 0.01 nag. 
There are various reasons why the purified capsular polysaccharides should 
be advantageous immunizing agents for man as compared with whole bacterial 
vaccines.  Not only should it be possible to avoid the local abscess formation 
associated not infrequently with whole pneumococcal vaccines, but in addition 
a stable, water-clear solution of known composition can be used.  It becomes 
possible also  to standardize  the  dose of antigen on a  weight basis.  It is of 
theoretical and  practical  importance  for each  of the  various pneumococcal 
types that a single, purified antigen relatively free from heterogeneous somatic 
constituents can be used.  Therefore, the injection of several purified capsular 
polysaccharides in a single does probably involves fewer antigens than when a 
whole bacterial vaccine of a  single  serological type is  used,  since the  whole 
bacterial  vaccine  contains  numerous  unrelated  protein  and  carbohydrate 
antigens in addition to the specific capsular polysaccharide. 
Ekwurzel,  Simmons, Dublin, and Felton (7) employed solutions of capsular poly- 
saccharides  for the immunization of man against pneumococcal  pneumonia over a 
4 year period between 1933 and 1937.  Volunteers in Civilian  Conservation Corps 
camps in New England and western United States were given a single subcutaneous 
injection of 1 mg. of each of the capsular polysaccharides of pneumococcus  types I 
and n  prepared by the calcium phosphate precipitation method of Felton, Kauffmann, 
and Stahl (8).  These polysaccharides  differed from those prepared in other labora- 
tories in that their injection into man gave rise to antibodies affording heterologous 
protection.  The specificity of the protective action of the antigens against pneumonia 
caused by pneumococcus types I and n  was not tested satisfactorily because of incom- 
plete typing of the organisms causing pneumonia.  The results in the western camps, 
however, appeared to indicate "that the antigen may be effective in reducing the case 
incidence of pneumonia." 
Suggestive  evidence of prophylactic effectiveness  of type I  polysaccharide was 
reported by Smillie, Warnock, and White (9) from a study of an epidemic of type I 
pneumonia in a mental institution in Massachusetts.  The preparation of polysac- 
charide used had properties similar to that described by Felton (10).  The epidemic 
subsided  shortly after the subcutaneous injection into most of the inmates of 2 mg. 
of polysaccharide.  Unfortunately, in this study it was not feasible to inject alternate 
subjects only, so that adequate controls were not available.  The prompt cessation 
of the epidemic following administration of the polysaccharide, however, indicates a 
specific protective action. 
Siegel and Muckenfuss  (11) studied in a  New York State mental hospital  the 
prophylactic effect of pneumococcal polysaccharides prepared by Felton.  A single 
subcutaneous injection of a solution containing 0.3 mg. of type I, 0.2 rag. of type II, 
and 0.15 rag. of type nI polysaccharide was given to one-third of the inmates.  An 448  PNEU3~OCOCCAL PNEUMONIA 
epidemic of type I pneumonia occurred in the institution subsequent to vaccination, 
but no evidence of a  specific protective effect  as concerned the disease was found. 
The cases of type II or type III pneumonia were too few to afford a test of the pro- 
phylactic effect  against these  types.  The antigenicity of  the  type I  preparation, 
however, must be considered as unsatisfactory, since specific antibodies, as measured 
by mouse protection tests, failed to appear in the serum of 11 out of 28 subjects within 
a period of 2 to 3 weeks following inoculation.  Moreover, none of the patients who 
developed type I pneumonia showed a significant rise in titre of type I antibodies in 
their serum following inoculation.  From the point of view of the antigenic response 
of the inoculated subjects, therefore, the study of Siegel and Muckenfuss was not a 
satisfactory test of antipneumococcal immunization in the prevention of pneumonia. 
The present paper deals with the  immunization of man with the polysac- 
charides of pneumococcus types I, II, V, and VII.  It has been demonstrated 
that a  single subcutaneous prophylactic injection of 0.03 to 0.06 nag. of each 
of these polysaccharides greatly diminished the incidence of pneumonia caused 
by  pneumococci of  the  same  types  in  immunized individuals.  Moreover, 
evidence will be presented that the incidence of pneumonia caused by types I, 
II, V, and VII in the non-immunized controls who were thoroughly mingled 
with the immunized was also reduced. 
Materials and Methods 
Pneumococcal Capsular Polysacckarides.--The capsular polysaccharides ofpneumococcus 
types I, II, and V were obtained  from E. R. Squibb and Sons and were prepared by the phenol 
method (12) in which heat and strong add or alkali are avoided.  A single lot of each was 
used throughout the study.  Two lots of type VII polysaccharide were employed.  The first 
of these was prepared by Dr. Rachel Brown and the second by Dr. John W. Palmer. a 
The solutions of polysaccharide were prepared  by dissolving them in isotonic saline to 
which 0.5 per cent phenol was added as preservative.  Sterilization was accomplished by 
filtration through Berkefeld candles.  Filtration introduced an uncertainty since it was not 
known how much of the polysaccharides would be adsorbed by the falter.  Adsorption  was 
greater than had been anticipated, so that in the first lot, 1 co. of solution, instead of containing 
0.06 rag. of each polysaccharide as had been intended, contained only about one-half of the 
expected amounts.  After 3755 men had been injected with a dose of 1 co. (about 0.03 rag. of 
each polysaccharide), the dosage was increased to 1.5 cc. (0.045 rag. of each polysaccharide). 
This amount was given to 2193 men. 
The second lot of polysaccharide solution, of which 1 cc. was injected, contained 0.06 rag. 
of type I and 0.05 rag. of type V polysaccharide per co., with presumably similar quantities 
of type II and type VII polysaccharides.  2638  men were injected with this lot.  The poly- 
saccharide content of the solution used for immunization was determined by quantitative 
precipitin titrafions with such analytical  sera as were available (13).  In the case of the type 
V and Vll polysaccharldes analytical  sera were not available.  Preliminary  studies in student 
volunteers had indicated that amounts of the pneumococcai polysaccharides of each of types 
I, II, V, and VII between 0.03 and 0.06 mg. injected  subcutaneously in a single injection 
evoke a definite antibody response, as measured by both the quantitative  precipitin (13) and 
x We are grateful to Dr. Rachel Brown of the New York State Department of Health and 
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mouse protection techniques.  The results of these studies will form the subject of separate 
communications. 
Determination of Antibody Response in Immunized Men.--Fifty  specimens of serum ob- 
tained before immunization with polysaccharides and a similar number obtained 3 to 6 weeks 
later are being analyzed for their antibody content by the quantitative precipitin technique. 
In addition serial specimens of serum have been obtained from a group of 8 men at intervals 
of 3 days over a period of 2 weeks in order to determine when an antibody response can  be 
first detected.  These sera have been tested by  the mouse protection technique. 
Detection of Pneumococcal Carriers.--Prior to and  during the immunization program  a 
continuous  carrier survey for pneumococci was carried  out.  The carrier survey included 
normal men in both the immunized and control groups, all hospital admissions for respiratory 
diseases, and a group of 100 surgical patients. 
A dry sterile swab was passed firmly across both tonsillar fauci and then across the posterior 
pharynx.  The swab was streaked immediately on the surface of a blood agar plate and then 
placed in broth containing 0.2 per cent glucose and rabbit blood (Avery tube).  Following 
incubation at 37°C. for 4½ hours,  0.5 to 0.75 cc. of the Avery tube culture was inoculated 
intraperitoneally into a white mouse and a direct Neufeld typing carried out on the remainder 
of the culture.  On the death of the mouse or upon sacrifice after 48 hours, a Neufeld typing 
was carried out on the peritoneal exudate.  The heart blood was cultured in plain broth 
containing rabbit blood and on a rabbit blood agar plate.  If no pneumocoeci were identified 
in the original Avery tube or mouse peritoneal exudate,  an attempt was made to isolate 
pneumococci from cultures of the mouse heart blood or from the original plate which had 
been  streaked  with  the  throat  swab.  Commercially prepared  antipneumococeai  serum, 
types I  to XXXIII, was used for typing by the Neufeld reaction.  In addition, sera for 15 of 
the pneumococcal types above XXXIII were used as a routine: 
Experience showed that none of the above steps could be omitted in the identification of 
pneumococci from pharyngeal swabs without materially lowering the number of positives. 
It should be noted that carrier rates for pneumococci of approximately 60 per cent were 
obtained by these methods in a sampling of 3462 men over a period of 7 months during the 
fall and winter of 1944-45. 
In addition to routine throat cultures, specimens of sputum were examined from all patients 
suspected  of having pneumonia.  For  the  identification  of pneumocoeci in  specimens of 
sputum, inoculation of mice was used as a routine during the winters of 1943-44 and 1944-45 
in addition to direct Neufeld typing of the sputum. 
The Background and Ckaracter of the 2Population 
The  experiment  was  carried  out  in  an  Army  Air  Force  Technical  School. 
There was much to recommend the choice of this population.  First, there was 
the  unusually  high pneumococcal pneumonia  rate  which had  prevailed in the 
School during the preceding two winters.  From  September  19,  1942,  to July 
1, 1944, more than 1500 cases of this disease occurred.  For a number of weekly 
periods the rate exceeded  150 admissions  per 1000 strength per annum,  which 
may be considered a  high epidemic level.  The curves of the pneumonia rates 
for both years were similar in their seasonal distribution.  Furthermore,  much 
J Sera for the 15 "higher" pneumoeoccal types were made available for this study through 
the courtesy of Miss Annabel Waiter, Bureau of Laboratories, New York City Department of 
Health.  We are also grateful to Miss Walter for the identification of a number of strains of 
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information was  available  concerning the  types of pneumococci responsible 
for these high disease rates.  During both the 1942-43  and 1943--44 seasons, 
type II accounted, on the average, for about 34 per cent of the cases of pneumo- 
coccal pneumonia.  Types I, V, and VII a.ccounted for slightly more than 9 
per cent each and types XII and IV followed with 7 and 5 per cent respectively. 
Since there had been no great change in the environment or the character of 
the troops, it was reasonable to expect that a  high incidence of pneumonia 
would occur during the winter of 1944-45  and a good surmise could be made 
as to which pneumococcal types would be prominent. 
Thorough epidemiological study of the respiratory disease experience of the 
preceding 2 years brought out another advantage in using the Technical School 
as an experimental population.  It was found that for each of the diseases 
investigated,  pneumococcal pneumonia,  streptococcal  sore  throat,  epidemic 
influenza, and common respiratory disease, the School reacted as a whole and 
not by its individual, component groups or units.  The reason for this was 
clear.  In contrast to troops of a  tactical or administrative unit, the men in 
the School spent the bulk of their day in close, indoor contact with one another. 
Furthermore, the men comprising a given School class came from several differ- 
ent squadrons and from many different barracks.  It is thus apparent that even 
should a  focus of disease appear in a  barrack, it would be spread rapidly to 
other barracks and other squadrons through the medium of schoolroom contact. 
All available data supported this assumption.  It is clear that from the point 
of  view of  experimental epidemiology this  uniform behavior  of  the  School 
population was a valuable trait. 
From yet another epidemiological aspect the population was highly saris- 
factory.  It is known that many factors such as seasoning and environment 
exert a large effect on the incidence of respiratory disease.  In the study of the 
Technical  School several  of  these  factors  could be  eliminated.  The  living 
conditions, duties, and even the recreations were identical for all the men in 
the School.  Where factors could not be eliminated they were susceptible to 
controlled study.  In order to insure this, a marginal punch card system was 
established by means of which the dates of arrival and departure, the basic 
epidemiological data, the immunization date, the respiratory disease experience, 
and, where pertinent, the pneumococcal carrier status were recorded for every 
man passing through the School.  It was thus a simple procedure at any time 
to compare the characteristics of the immunized and control groups.  Table I 
shows such a  comparison made on the entire student body in late February, 
1945,  and includes data on length of service, age distribution, and previous 
history of pneumonia. 
It is apparent from the data shown in Table I  that there was no essential 
difference between the two groups in respect to length of service, age distribu. 
tion, and previous history of pneumonia.  Similar samplings were taken ir 
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The average duration of stay in the School was 6 months which in a military 
population may be considered as long. 
Finally, as discussed under Methods, facilities were available for extensive 
TABLE I 
Length of Service, Age Distribution, and Previous Hislory of Pneumonia in Immunized 
and Non-Immunized Groups 
Distribution  according to length of service 
Length of service  Immunized  subjects  Non-hnmunlsed  subjects 
yrs. 
2/12 
4/12 
6/12 
8/12 
10/12 
12/12 
More than i 
~er Cent 
6.0 
7.3 
2.1 
1.8 
2.3 
5.1 
75.4 
per ceng 
6.6 
7.4 
2.4 
2.0 
2.1 
5.3 
74.2 
Total  ......  100.0  100.0 
Distribution  according  to age 
Age  Immunized  subjects  Non-lmmunized  subjects 
yrs. 
18-20 
21-23 
24-26 
27-29 
30-32 
More than 32 
per c$n~ 
30.1 
25.6 
22.8 
12.8 
5.9 
2.8 
~er cent 
30.8 
24.6 
24.4 
11.9 
5.2 
3.1 
Total .........................  100.0  100.0 
Distribution  according  to previous  history  of pneumonia  (all varieties) 
History of pneumonia  I  Immunized  subjects  Non-immunized  subjects 
per cent  per cent 
Positive ........................  19.3  16.9 
Negative ........................  .  80.7  83.1 
and accurate typing of pneumococci both in hospital admissions and in the 
healthy population. 
Immunization with Polysaccharides 
Over a period of 5 days beginning  September 20, 1944, the component squad- 
rons of the Technical School were run through injection lines.  A barrack was 
roped off longitudinally  and as a  squadron filed in, it was allowed to divide at 452  PNEUMOCOCCAL  PNEUMONIA 
random.  Men passing down one side of the barrack received the polysaccharide 
solution subcutaneously; those passing down the other side received an injec- 
tion of 1 cc. of sterile isotonic saline containing 0.5 per cent phenol.  At the 
end of the 5 days 3755 men had received the polysaccharides and 3975 had been 
injected with saline.  Mter this time, new men arriving at the School received 
the polysaccharides or saline alternately.  In all, 8586 men were injected with 
the polysaccharides and 8449 with saline.  By this means the population of 
the School was kept almost equally divided into immunized and non-immunized 
fractions.  In all the day by day activities of the troops the intermingling of 
immunized and non-immunized subjects was complete.  Calculation of man- 
days  of  exposure  gives  approximately  equal  figures  for  immunized  and 
non-immunized, 745,997 and 772,898 respectively. 
TABLE II 
Incidence oJ Pneumonia  in Immunized and Non-Immunized Groups 
Man-days  exposure  .......................................  74,5,997  772,898 
Type of pneumonia  Immunized group  Non-immunized group 
I .........................................  2  2 
II .........................................  1  14 
V .........................................  1  4 
VII .........................................  0  6 
Total of types I, II, V, and VII ..............  4  26 
IV .........................................  8  6 
XII .........................................  21  25 
Other types ..................................  27  28 
Reactions to the injection were mild.  A fair proportion of those injected 
with polysaccharide complained of sorness of the arm lasting 3 to 4 days.  This 
did not interfere with their usual activities.  Three  men were  admitted to 
hospital with systemic reactions attributed to  the  injection.  All recovered 
promptly.  The reactions to phenolized saline were negligible. 
Effect of Immunization  on the Development of Clinical Pneumonia 
The effect of immunization on the  development of clinical pneumonia is 
shown in Table  II.  During  the  7  months period  of  observation  following 
the  beginning  of  the  immunization program,  4  cases  of pneumonia caused 
by types I,  II, V,  or VII occurred in the immunized group as opposed to 26 
cases among the non-lmmunized subjects.  This difference is highly significant. 
When the individual types are considered, it is apparent that the one to fourteen 
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value of immunization with the polysaccharide of this type.  The numbers of 
cases for types  I,  V,  and  VII  were  too  small  to permit  definite statistical 
conclusions, although the zero to six difference in type VII would be due to 
chance only once in about four hundred times.  Despite the inconclusiveness 
of the results for these three types, there is no reason for believing that polysac- 
charides of types I, V, and VII should differ in their immunizing capacity from 
the polysaccharide of type II.  Furthermore, as will be shown in the discussion 
of the effect of the immunization program on the non-immune half of the popu- 
TABLE III 
Interval between  Injection and the De~dopment of  Pneumonia in Immunized and Non-Immunized 
Subjects 
Interval 
1 
2 
3 
4 
6 
8 
10 
12 
14 
16 
16+ 
Total...  t 
No. of cases of pneumonia 
Types I, II, V, VII 
in immunized 
subjects 
ypes I, II, V, VII 
n non-immunized 
subjects 
0 
3 
3 
2 
2 
2 
1 
0 
2 
3 
8 
26 
All other types 
in immumzed 
subjects 
1 
5 
7 
8 
6 
3 
4 
2 
2 
2 
16 
56 
All other types in 
non-immunized 
subjects 
1 
3 
5 
12 
7 
4 
4 
4 
1 
4 
14 
59 
lation, the paucity of cases of types I, V, and VII pneumonia is in itself evidence 
of the effectiveness of the immunizing agents. 
The  distribution  between  the  immunized  and  non-immunized  groups  of 
pneumonia due to types other than  I,  II,  V,  and VII adds  validity to the 
differences noted in the distribution of the types against which immunization 
was practised.  For type XII, which was the chief cause of bacterial pneumonia 
during the winter of 1944-45, 21 cases occurred in the immunized group and 25 
cases  among  the  controls.  Type  IV,  which  ranked  second  in  importance, 
caused eight cases of pneumonia in the immunized and six in the non-immunized 
group.  Pneumonia due to other types also was divided evenly, there being 
27 and 28 cases respectively  among the immunized and non-immunized subjects. 
The four immunized men who developed pneumonia all did so within the 
first 2  weeks following the  immunizing injection.  In Table III and  Fig.  1, 454  PNEUMOCOCCAL  PNEUMONIA 
this  distribution is  contrasted with that  of non-immunized men developing 
type I, II, V, or VII pneumonia and with immunized and non-immuniTed men 
who developed pneumonia due to other types.  It is clear that the distribution 
of pneumonia in the three control groups as shown in the lower three curves 
of Fig. 1, was closely similar, and that the cases were scattered throughout the 
period in which the men were under observation.  The concentration of control 
group cases in the first 6 weeks after injection is in keeping with the known 
behavior of pneumonia in the Technical School.  Repeated observations had 
shown that more than half the cases of pneumonia developed during the first 
lilt 
< 
0 
0 
Ig 
ILl 
m 
D 
Z 
Types I-TL~X[I[- (Im rn u ni zed ) 
~  .Types I.TI"7-'~ZII"  (Non-immunized') 
4 
2 
0 
12 
O%her Types (Immunized) 
6 
4 
2 
OCherTypes (Non-immunized) 
o  a  4  ¢  8  1o  la  14.  16  is  go  2z  24- 
INTERVAl  IN  WEEKS 
Fro.  1.  Interval between injection and the development of pneumonia in immunized and 
non-immunized subjects. 
6 weeks after arrival.  In the majority of subjects in this study the date of 
arrival coincided with the date of injection. 
The actual intervals between injection and admission to the hospital with 
pneumonia for the four immunized cases were 2, 6, 7, and 11 days respectively. 
It is believed that these cases may have occurred before specific immunity had 
developed to the fuU extent. 
Time Required  for Appearance of Circulating Antibodies Following Injection 
of Polysaccharides.-- 
Specimens of serum were obtained from eight men immediately preceding injection of the 
polysaccharides, at 3 day intervals thereafter for a period of 2 weeks, and a final specimen at 
25 days.  The presence of antibodies was determined by means of protection tests in mice C. M. MACLEOD, R.  G. HODGES, ~[. HEIDELBERGER, AND W.  G.  BER.N'HAP.D 455 
using 0.2 cc. of serum and 100 M.L.D. of pneumococci of the same serological types as were 
represented in the polysaccharide solution used for immunization.  Serum  was diluted to a 
volume of 0.5 cc. and mixed with an equal volume of broth containing the infecting dose of 
pneumococci immediately before injection.  Three  mice were used  for  each  test.  The 
animals were observed for 5 to 7 days following infection.  The results of these tests are 
shown in Table IV. 
From the data shown in Table IV it can be seen that immunity to pneumo- 
cocci types I, II, V, and VII developed between 6 and 9 days after injection of 
the polysaccharides as estimated by the appearance in the serum of antibodies 
protective  for mice.  All  subjects  showed  antibodies  for all  of  the  polysac- 
charides within a 9 day period following injection.  Certain of them possessed 
antibodies to one or another pneumococcal type before injection.  The incidence 
TABLE  IV 
Number of Days Required  for Appearance of Antibody in the Serum of Subjects Injected 
Subcutaneously with Pneumococcal Pdysaccharides 
Pneumococcal type 
Subject 
I  II  V  VII 
9 
0 
9 
9 
6 
6 
9 
0 
9 
0 
9 
6 
9 
9 
0 
9 
9 
0 
0 
6 
6 
0 
0 
0 
0 indicates that antibody was present before injection of polysaccharides. 
in the general population of immunity to pneumococcus types I, II, V and VII 
was not determined.  It might be expected that the incidence of immunity in 
the subjects listed in Table IV would be higher than in the general population 
since  these  individuals  were  all  members  of  the  permanent  party  (medical 
detachment)  and had been present on the post for a  considerable  time with 
more opportunity for exposure to these types. 
Dural/ion of Immunity.--An upper limit for the duration of immunity could 
not be determined in  the present  study.  However, a  large number of men 
were under observation for 6 months, which may be set, therefore, as a minimum 
for the  duration  of the  immune effect.  On  the  basis of previous studies  in 
human volunteers  (14)  it seems probable that immunity as indicated by the 
presence of antibodies should endure for a period of at least 1 year, since anti- 
body levels of ½ to ½ the original maximum level were still present after a period 
of 1 to 2 years in most subjects. 456  PNEUMOCOCCAL  PIq'EUMONIA 
Effect  of Immunization  on  the  Pneumococeal  Carrier  Rates 
Determination of pneumococcal carrier rates was made continuously through- 
out  the  course  of  the  study.  Pneumococci  of  various  specific  types  were 
identified  in  1212  instances  out  of  1785  cultures  from immunized men  (68.0 
per cent) and in 1295 instances out of 1810 cultures from the non-immunized 
group (71.6 per cent).  Pneumococci of more than one type were encountered 
in a considerable proportion of cultures.  In Table V each of the types identified 
is scored as one regardless of how many other types were isolated from the same 
individual, so that this table shows the frequency with which the various types 
were encountered in the population and not the proportion of men who were 
TABLE V 
Distribution of Individual Types of Fneumococci between Immunized and Non-Immunized 
Groups 
(Excluding Cases of Pneumoeoccal Pneumonia) 
Immunized men  Non-immunized  men 
Pneumococcal type 
Number  Per cent  Number  Per cent 
I ............................  6  0.3  12  0.7 
II  ............................  14  0.8  30  1.7 
V ............................  1  0. I  5  0.3 
VII  ..... . .....................  11  0.6  12  0.7 
Total I, II, V, and VII  ........  32  1.79  59  3.26 
XII  ............................  127  7.1  139  7.6 
All other types .................  1053  59.1  1099  60.8 
Total of all types .............  1212  68.0  1295  71.6 
Total cultures taken ...........  1785  1810 
pneumococcal carriers.  57.7 per cent of the total population were found to be 
carrying pneumococci of one or more types. 
Thirty-two men in the immunized group and fifty-nine in the non-immunized 
carried pneumococcus types I, II, V, or VII, or 1.79 and 3.26 per cent~respec- 
tively.  This is a  significant difference  (x  2 =  9.0).  This  difference becomes 
highly significant when the numbers of carriers in the two groups who developed 
clinical pneumonia  are  added  to the  figures for healthy  carriers  in Table  V. 
Four  men  in  the  immunized  group  and  twenty-six  in  the  non-immunized 
developed pneumonia due to types I, II, V, or VII.  These were case carriers. 
The total carrier incidence for these types in the immunized group, therefore, 
was 36 and in the non-immunized 85  (x  ~ =  27.0).  From these  data  it may 
be concluded that the carrier rate for pneumococci of types I, II, V, and VII C. M. IL~LEOD, R. G. HODGES, ~. HEIDELBEEGER, AND W. G. BERNHARD  4~ 
was significantly lowered in the immunized group, in all likelihood as a conse- 
quence of immunization. 
It is probable that the carrier rates for types I, II, V, and VII were reduced 
not only in the immunized but in the non-immunized group as well.  From 
Table V it can be seen that the carrier rate for pneumococcus type XII was 7.1 
per cent in the immunized and 7.6 per cent in the non-immunized; that is, 
the rates were approximately equal.  The high carrier rate for type XII takes 
on great significance when it is recalled that this type was responsible for more 
cases of pneumonia in the Technical School than any other single type during 
the 1944-45  season. 
Previous studies such as those of stinman (15),  Smillie  (16),  Sydenstricker 
and Sutton (17),  Strom (18), and Gilman and Anderson (19) have shown that 
during outbreaks of pneumococcal pneumonia in institutions or isolated com- 
munities, high carrier rates for the infecting types are encountered among the 
unaffected portion of the population.  Carrier rates as high as 6 to 10 per cent 
were encountered in these studies.  In the present study the same has been 
found true for type XII which caused epidemic disease and was present in 7.3 
per cent of 3595 cultures examined. 
While carrier rates for pneumococci of types I,  II,  V,  and VII were  not 
determined during the winter of 1942--43 and 1943-44  when these types were 
causing epidemic disease, it is probable that high carrier rates for these types 
were present during these epidemic seasons.  It is suggested that immunizing 
one-half of the School population not only was effective in reducing the carrier 
rate for types I, II, V, and VII in the immunized group, as shown above, but 
also aided in preventing the  development of high carrier rates  in  the  non- 
immunized  population.  In the  succeeding  section  of  this  paper,  further 
evidence bearing on these points is discussed. 
The Effect of Immunization on the Incidence of Pneumonia in the Non-Immunized 
Half of the Population 
Of equal importance with the prevention of types I, II, V, and VII pneumonia 
in immunized subjects was the reduction of infection due to these types in the 
non-immune half of the population.  As has been stated above, based on the 
experience of the two preceding winters it was expected that large numbers of 
cases of pneumonia caused by these types would occur during the period of 
observation.  This  expectation  was  not  fulfilled.  The  reason  for  the  dis- 
crepancy became clear when the behavior of type XII and type IV pneumonia 
was studied for the 3 years in question.  Fig. 2 contrasts the admission rates 
in 1942-43,  1943-44,  and 1944-45  for pneumonia due to types I, II, V, VII, 
XII, and IV.  The curves are aligned so that the corresponding 4 week periods 
for the 3 years occupy the same position on the abscissa.  The rates for the 
first winter begin with January, 1943, since typing of pneumococci before that 
time was not sufficiently  complete.  It is apparent that the curves for type XII 458  PNEIY~0COCCAI,  PNEIY~ONIA 
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pneumonia are similar both in size  and shape for the  3 years.  The same is 
true for type IV although the small number of cases introduces some irregu- 
larity.  It is also apparent that the 1943 and 1943--44 curves for types I, II, v, 
and VII respectively are closely similar.  However, when the  1944-45 curves 
for types I, II, v, and VII in the  non-immunized part of the population are 
TABLE VI 
Expected and Observed Incidence of Type I, II, V, and VII Pneumonia  in Non-Immunized 
Group for 191  A, A.5 
Calculated from behavior of type XII 
Type ................................... 
Expected from 1942-43 experience. 
Expected from 1943-44  experience. 
Observed 1944-45 (times 2) ....... 
I 
57 
II 
170 
182 
30 
V 
62  82 
12 
VII 
No. of cases of 
type XII used 
for calculating 
expected 
incidence* 
29 
43 
47 
Calculated from behavior of t~ ~e IV 
Type ................................... 
Expected from 1942-43 experience. 
Expected from 1943--44  experience. 
Observed 1944-45 (times 2) ....... 
I 
25 
49 
4 
II 
182 
30 
V 
26 
47 
6 
VII 
56 
No. of eases of 
type IV used 
for calculating 
expected 
incidence* 
20 
13 
14 
Average expected for 1944-45 
Type 
I 
II 
V 
VII 
NO. of cases 
44 
153 
45 
53 
* These figures represent the actual numbers of cases of type XII and type IV pneumonia 
occurring for each of the 3 years in both immunized and non-immunized  groups. 
examined, it is evident that the rates fall far below the experience of the pre- 
ceding 2 years.  The consistent behavior of type XII and of type IV in each 
of the 3 years provides a means for calculating the amount of reduction in the 
incidence  of  pneumonia  caused  by  types  I,  II,  V,  and  VII among the 
non-irnmunes which was brought about by immunizing one-half the population. 
In Table VI the expected incidence of type I, II, V, and VII pneumonia for 
the 1944-45 season is shown as calculated on four different bases.  The values 
based on the 1943-44 experience were almost identical when either the type XII 460  PN'EUMOCOCCAL PN'EUMONIA 
or type IV incidence was used in the proportions.  The values based on the 
1942-43 experience showed a greater divergence, part of which may be due to 
the incomplete typing of pneumococci at that time.  The observed incidence 
for 1944-45 was multiplied by two since the non-immunes  represented  only 
one-half  the population.  In  Fig.  3  the  expected  and  observed  values are 
presented diagrammatically, the expected  values being the average  of values 
calculated on the four different bases.  The observed incidence of pneumonia 
due to types I, II, V, and VII in the non-immunized men during 1944-45 was 
17.6 per cent of the expected incidence. 
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Fio. 3. Expected and observed incidence of pneumococcal pneumonia caused by types I, 
II, V, and VII for 1944-45.  The observed incidence for 1944--45 has been multiplied  by two 
since the non-immunes comprised only one-half the population. 
The  conclusion  is  inescapable  that  immunization of half the  population 
greatly reduced the incidence of disease in the non-immune half.  It explains 
why the number of cases available  for testing the effect of the immunization 
was so far below the expected.  Furthermore, the almost identical reduction 
in the incidence of pneumonia caused  by each of the four types among the 
non-immunes, affords very strong evidence that immunization with the capsu- 
lar polysaccharides  of types I, V, and VII was just as effective as the more 
easily visualized  protection given by the polysaccharide  of type II.  Since 
the actual number of cases of type I, V, and VII pneumonia was insufficient 
to give statistical proof of the value of these  polysaccharides  as immunizing 
agents, the evidence afforded by the comparisons  with the preceding years is 
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Two possible explanations may be suggested  to account for the protection 
afforded the non-immune half of the population.  In the first place, elimination 
of type I, II, V, and VII pneumonia in half the population produced a corre- 
sponding reduction in case-contact  carriers  and thus lowered the carrier rate 
of the whole population.  This assumes that the principal focus for dissemina- 
tion  was  from  subjects  just  developing  pneumonia  or  recently recovered. 
In the preceding  2 years, when the pneumonia rates were very high, the r61e 
of cases in disseminating the organisms may have been important.  For 1944- 
45, however, it is hard to believe that 43 cases of type XII pneumonia, occurring 
during the 4 months between January 6 and April 27, could account for a type 
XII carrier rate averaging 12.7 per cent over the same period. 
A second possibility  is that the immunization directly affected the carrier 
rate.  It has already been shown that there was a highly significant difference 
between the I, II, V, and VII carrier rates of the immunized and non-immunized 
men.  It is probable that the truth lies in a combination of the two explanations. 
With the thorough mixing of the immunized and non-immunized  subjects  in 
the population, the chances would be that in every other one of its transfers 
from man to man, the pneumococci would fall on infertile ground, either because 
the subject was prevented from developing pneumonia or because his ability 
to carry pneumococci was lessened by the immunization.  The net result would 
be a  lowering of the carrier  rate for types I, II, V, and VII throughout the 
entire population. 
The reduction of disease in the non-immune portion of a partially immunized 
population is not a new finding.  Similar observations have been made follow- 
ing immunization against diphtheria.  Likewise, Lister (20) concluded that in 
antipneumococcal  immunization with  bacterial  vaccines,  the  unimmunized 
portion of the population derived benefit  from contact with the immunized 
portion.  He was unable to compute the magnitude of this benefit. 
P/SU~  AND DISCUSSmN 
In previous studies  on the effect  of antipneumococcal Immunization ill  the 
prevention of pneumococcal pneumonia certain factors have made evaluation 
¢Hfficult.  In the present study, it is believed that the important sources of 
error have been eliminated, and that as a result, the interpretation of the results 
can be made with more assurance than has been previously possible. 
The population chosen, that of an Army Air Force  Technical  School, was 
large.  During the two preceding  winters,  high epidemic  rates for pneumo- 
coccal pneumonia had prevailed in the School.  Information on the serological 
types of pneumococci identified from the 1500 cases of pneumonia occurring 
in the first 2 years was available.  Types II, I, V, VII, XII, and IV, in that 
order, caused 75 per cent of the cases of disease, the rates for the individual 
types being approximately the same for each of the 2 years.  The living condi- 
tions and duties of the population, which had been remarkably uniform during 462  PNEUMOCOCCAL  PNEUMONIA 
the 1942-43 and 1943-44 seasons, were unchanged during the season of 1944-45. 
A reasonable prediction could thus be made that. the incidence of pneumococcal 
pneumonia during the experimental period  would be high and also what types 
of pneumococci would be involved.  Accordingly, the solution used for immuni- 
zation contained the specific capsular polysaccharides  of pneumococcus types 
I, II, V, and VII.  Type XII and type IV remained as controls. 
The preparations of polysaccha~ides were of known antigenic potency as 
determined previously by inoculation  of civilian volunteers. 
Immunization by a  single subcutaneous  injection of the  polysaccharides 
was carried out on alternate members of the population, thus insuring a thor- 
ough mixing of immunized and non-immunized subjects  in all phases of their 
activities.  To make certain that the two groups were epidemiologicaUy identi- 
cal a marginal punch card system was devised which made it possible at any 
time to compare the groups for such factors as length of military service, age, 
and previous history of pneumonia.  At no time was any essential  difference 
found.  Computation of the man-days of exposure gave approximately equal 
values for the two groups.  Finally, the members of the population could be 
observed for a reasonably long time, since the students remained at the School 
for 24 weeks. 
Laboratory facilities were available for the typing of all cases of pneumonia. 
In  addition,  a  continuous carrier  survey for  pneumococci  was  carried  on 
throughout the period of observation,  the total sample being 3757 pharyngeal 
cultures with an over-all pneumococcal carrier rate of 57.7 per cent. 
The evidence given in the present paper demonstrates clearly that immuniza- 
tion of man with the specific capsular polysaccharides  of pneumococcus types 
I, II, V, and VII is effective in preventing the development of pneumonia due 
to these types in the immunized subjects.  Of equal interest is the observation 
that immunization of half the population against types I, II, V, and VII greatly 
reduced the incidence of pneumonia due to these types in the non-immunized 
subjects.  This conclusion was based  on the observed  behavior  of type XII 
and of type IV.  For each of these types the rates of pneumonia were closely 
similar for the 1942-43, the 1943-44, and 1944-45 seasons.  Furthermore, the 
ratios of the incidence of type XII pneumonia to the incidence of type I, II, 
V, and VII pneumonia,  respectively,  were quite similar for the  1942-43 and 
the 1943-44 seasons.  The ratios of type IV pneumonia to the types I, II, V, 
and VII pneumonias  were also close for the two seasons.  From the actual 
incidence of type XII and type IV pneumonias  in the 1944-45 season, it was 
thus possible to calculate  on four different  bases the expected  incidences of 
type I, II, V, and VII pneumonias  for the winter of 1944-45.  The expected 
incidences obtained from the four separate  calculations  were close.  The ob- 
served incidence of type I, II, V, and VII pneumonia in the non-immunized 
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Earlier studies by other investigators have shown that when pneumococcal 
pneumonia is epidemic the carrier rates for the epidemic types are high.  The 
same has been shown to be true for pneumococcus type XII during the present 
study.  It is probable that  the failure of the non-immunized portion of the 
population  to  develop high  pneumonia  rates  was  due  to  inhibition  of  the 
development of high carrier rates for types I, II, V, and VII as a consequence 
of its being thoroughly mixed with the immunized portion.  In this regard, 
evidence has been presented that  the carrier rates for these types in the im- 
munized portion of the population were  significantly  lower than  in the non- 
immunized.  It should also be considered that the elimination of pneumonia 
cases in half the population should bring about a  comparable elimination  of 
case-contact carriers.  For these reasons,  it is suggested that the ability of the 
immunized subjects to carry and disseminate types I, II, V, and VII pneumo- 
cocci was greatly reduced by specific immunity to these types and that  this 
immune barrier, composed of half the population, greatly reduced the dissemi- 
nation of these types throughout the whole population. 
It is realized that a high carrier rate for pneumococci of certain serological 
types is only one of the factors responsible for epidemic outbreaks of pneumonia. 
For example, the association of pneumococcal pneumonia with non-bacterial 
~espiratory disease has longbeen recognized.  The carrier rate for pneumococci 
of certain types, however, is of sufficient importance in the production of high 
pneumonia  rates  that  it  is probable that  any procedure which inhibits  the 
development of a high carrier rate will also reduce the incidence  of pneumonia. 
The time required for the development of immunity following  injection of 
the polysaccharides is believed to be in the neighborhood of 2 weeks.  This is 
based on the observation that the only cases of pneumonia among the immun- 
ized men that were caused by types I, II, V, and VII developed during  the 
first 2 weeks after immunization.  In support of this conclusion,  studies on 
the serum of immunized individuals showed that specific antibodies developed 
within this time but usually required 3 to 6 weeks to reach their maximum (14). 
Because  of  the  relatively  low  incidence  of  pneumococcal pneumonia  in 
civilian  populations, antipneumococcal immunization is unlikely to become a 
general  procedure.  In  certain  groups  at  greater  risk,  for example  foundry 
workers, miners,  and inmates of mental institutions,  however, immunization 
would appear to be a desirable procedure.  In military populations the greatest 
incidence  of pneumonia occurs in new recruits, so that most benefit would be 
derived from immunization  of this group.  Although  it cannot  be predicted 
in advance with complete assurance, it is probable that the immunizing prepara- 
tion  should  contain  the  capsular polysaccharides  of pneumococcus types I, 
II, V, VII, XII, and possibly that of type IV also.  Experience in two other 
military installations in which a moderately high incidence has prevailed during 
the past 3 years has shown that these types were responsible for most of the 464  PNEU~OCOCCAL  PNEUMONIA 
cases of pneumococcal pneumonia.  Epidemics recorded among civilian groups 
in the United States and Europe almost without exception have been mused by 
pneumococcns types I, l-I, and V.  It is of considerable interest, however, that 
pneumococcus type XH, which has previously not been considered of epidemic 
significance in this country, has also been important in the etiology of pneu- 
monia among the laborers in South African mines where epidemic levels have 
prevailed. 
SUMMARY  AND  CONCLUSIONS 
1.  Tmmunization of man  with 0.03  to  0.06  rag.  of each  of  the  capsular 
polysaccharides of pneumococcus types I, H, V, and VII, given in a  single 
subcutaneous injection, has been shown to be effective in preventing pneu- 
monia caused by these types but not that due to heterologons types. 
2.  Tmmunity appears within a period of 2 weeks following injection of the 
polysaccharides.  Its  duration was not determined, although 6  months can 
be set as a minimum. 
3.  Immunization of  alternate subjects  in  the  population reduced greatly 
the incidence of pneumonia in the non-immunized. 
4.  The carrier rate for pneumococcus types I, II, V~ and VII was lowered 
significantly in the immuniTed group as compared with the controls.  It is 
suggested that an over-all reduction in the incidence of carriers was responsible 
for the lowered rates for pneumococcal pneumonia in the non-immunized group. 
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